As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus, indications and presenting the biomarker portfolio.

In the interview done by Venturelab, Peter talks about the challenges of an entrepreneur. As the CEO of a start-up, a strong make it happen mentality, and the support of a smart and experienced team is crucial.

In an interview with Investiere our founder and scientific advisor Prof. Dr. Manfred Claassen describes how our understanding of biology is advancing thanks to technological progress. Scailyte is on a mission to save millions of lives by developing single-cell precision diagnostics.

Making a diagnosis can be a tricky endeavour. For instance, diagnosing skin T-cell lymphoma, a rare form of cancer for which early detection can greatly boost survival, takes on average six years, because the skin rashes associated with it are difficult to interpret.

Scailyte is among the ten selected young science-based university spinoff companies that showcase their visions and strategies in the final rounds of a new award created by Nature Research and Merck.

Scailyte raises CHF 3.1 million in a pre-series A financing round led by Swisscom Ventures to further advance its biomarker discovery platform.

Scailyte and CHU Rennes have made an initial discovery of a single-cell

ScailyteTM is an ETH Zürich Spin-off and Top100 Swiss Startup applying artificial intelligence to
discover novel and ultra-sensitive biomarkers from single-cell data.

Scailyte ranked among the top100 Swiss startups in 2019. We are unlocking the full potential of Single-Cell Data, which will drive breakthrough discovery in healthcare.